GoodRx Holdings, Inc. $GDRX Shares Purchased by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. boosted its position in GoodRx Holdings, Inc. (NASDAQ:GDRX) by 16.5% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,671,521 shares of the company’s stock after purchasing an additional 236,896 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned about 0.47% of GoodRx worth $8,324,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in GDRX. Bordeaux Wealth Advisors LLC grew its holdings in shares of GoodRx by 64.6% during the second quarter. Bordeaux Wealth Advisors LLC now owns 61,319 shares of the company’s stock worth $305,000 after buying an additional 24,057 shares in the last quarter. Pathway Capital Management LP purchased a new stake in GoodRx during the 2nd quarter valued at about $2,906,000. Teacher Retirement System of Texas raised its holdings in GoodRx by 99.1% in the 2nd quarter. Teacher Retirement System of Texas now owns 98,371 shares of the company’s stock valued at $490,000 after acquiring an additional 48,966 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in GoodRx in the 2nd quarter worth approximately $981,000. Finally, Vontobel Holding Ltd. acquired a new position in shares of GoodRx during the 2nd quarter worth approximately $58,000. Institutional investors and hedge funds own 63.77% of the company’s stock.

Insider Transactions at GoodRx

In other GoodRx news, major shareholder Equity Vii L.P. Spectrum sold 23,771 shares of the business’s stock in a transaction that occurred on Wednesday, October 15th. The stock was sold at an average price of $4.00, for a total value of $95,084.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 4.53% of the stock is currently owned by insiders.

GoodRx Stock Up 1.0%

Shares of NASDAQ:GDRX opened at $3.06 on Thursday. The company has a market capitalization of $1.06 billion, a price-to-earnings ratio of 34.00, a PEG ratio of 1.56 and a beta of 1.19. GoodRx Holdings, Inc. has a 12-month low of $2.95 and a 12-month high of $5.81. The business has a 50-day moving average price of $3.95 and a 200 day moving average price of $4.25. The company has a current ratio of 3.11, a quick ratio of 3.11 and a debt-to-equity ratio of 0.81.

GoodRx (NASDAQ:GDRX) last announced its earnings results on Tuesday, November 4th. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.01). GoodRx had a return on equity of 9.73% and a net margin of 3.97%.The company had revenue of $196.03 million for the quarter, compared to analysts’ expectations of $195.17 million. During the same period last year, the business earned $0.08 EPS. The company’s quarterly revenue was up .4% compared to the same quarter last year. GoodRx has set its FY 2025 guidance at EPS. Sell-side analysts expect that GoodRx Holdings, Inc. will post 0.13 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. UBS Group cut their price target on GoodRx from $4.25 to $4.00 and set a “neutral” rating for the company in a report on Thursday, November 6th. Weiss Ratings cut GoodRx from a “hold (c-)” rating to a “sell (d+)” rating in a report on Saturday, October 25th. Mizuho reduced their price target on GoodRx from $5.00 to $4.00 and set a “neutral” rating on the stock in a report on Thursday, November 6th. Raymond James Financial cut shares of GoodRx from a “strong-buy” rating to an “outperform” rating in a research report on Friday, August 8th. Finally, TD Cowen cut their price objective on shares of GoodRx from $7.00 to $6.00 and set a “buy” rating for the company in a research report on Monday. Six investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $5.52.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.